Pasar al contenido principal

EVALUACION IN VITRO E IN VIVO DE NUEVOS NANOPORTADORES PARA ADMINISTRACION INTRANASAL EN EL TRATAMIENTO Y DIAGNOSTICO DE ENFERMEDADES CEREBRALES.

PID2021-127983OB-C22

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD AUTONOMA DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mussel-Inspired Multifunctional Polyethylene Glycol Nanoparticle Interfaces

  • Casagualda Clapés, Carolina|||0000-0002-6160-6730
  • López Moral, Alba|||0000-0003-0864-0339
  • Alfonso Triguero, Paula|||0000-0002-6554-5656
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Alibés, Ramon|||0000-0002-7997-2691
  • Busqué, Félix|||0000-0001-7566-4264
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
Nanoparticles (NPs) are receiving increasing interest in biomedical applications. However, due to their large surface area, in physiological environments, they tend to interact with plasma proteins, inducing their agglomeration and ultimately resulting in a substantial efficiency decrease in diagnostic and therapeutic applications. To overcome such problems, NPs are typically coated with a layer of hydrophilic and biocompatible polymers, such as PEG chains. However, few examples exist in which this property could be systematically fine-tuned and combined with added properties, such as emission. Herein, we report a novel mussel-inspired catechol-based strategy to obtain biocompatible and multifunctional coatings, using a previously developed polymerization methodology based on the formation of disulfide bridges under mild oxidative conditions. Two families of NPs were selected as the proof of concept: mesoporous silica NPs (MSNPs), due to their stability and known applications, and magnetite NPs (FeO NPs), due to their small size (<10 nm) and magnetic properties. The PEG coating confers biocompatibility on the NPs and can be further functionalized with bioactive molecules, such as glucose units, through the end carboxylic acid moieties. Once we demonstrated the feasibility of our approach to obtaining PEG-based coatings on different families of NPs, we also obtained multifunctional coatings by incorporating fluorescein functionalities. The resulting coatings not only confer biocompatibility and excellent cell internalization, but also allow for the imaging and tracking of NPs within cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multimodal HOCl-responsive MEH-PPV nanoparticles for anti-inflammatory imaging and therapy

  • Villar-Alvarez, Eva|||0000-0003-4023-1375
  • Parron-Onate, Sara
  • Wienskowska, Olga
  • Carrascull-Marín, Aleix
  • Bellacanzone, Christian|||0000-0002-1986-6440
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
  • Roscini, Claudio|||0000-0002-0157-8934
Inflammatory disorders often correlate with an unusually high intracellular production of hypochlorous acid (HOCl). Therefore, its rapid, sensitive, and specific detection is crucial for an early diagnosis and treatment evaluation. While nanoparticles for detection have already been reported, multimodal nanoparticles that simultaneously detect and eliminate reactive oxygen species (including the excess of HOCl) are scarce despite their interest. Herein, we developed highly selective fluorescent nanoparticles using the copolymer poly(2-methoxy-5-(2-ethylhexyloxy)-1, 4-phenylenevinylene) (MEH-PPV), with (MEH@CS) and without a chitosan coating (MEH). The conjugated polymer is oxidized in the presence of HOCl, exhibiting a rapid (in less than 30 s) and sensitive fluorescence turn-off response with a log-log linear HOCl relationship within dynamic ranges of ≈ 0.784-83 μM and ≈ 0.384-55 μM for MEH and MEH@CS NPs, respectively, allowing to monitor basal HOCl levels within the standard physiological concentration range (5 - 25 μM) and its differentiation from overproduction. Moreover, the nanoparticles can encapsulate and release quercetin (a powerful natural scavenger for HOCl), leading not only to monitoring but also to a reduction in pro-inflammatory cytokines of inflammation-stimulated macrophage cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma

  • Jiménez, Rafael|||0000-0003-4103-8219
  • Constantinescu, Andrada
  • Yazir, Muhube
  • Alfonso Triguero, Paula|||0000-0002-6554-5656
  • Pequerul Pavón, Raquel|||0000-0002-0008-975X
  • Parés i Casasampera, Xavier|||0000-0002-5071-9465
  • Pérez-Alea, Mileidys|||0000-0002-8739-8087
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Farrés, Jaume|||0000-0001-9069-3987
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
Glioblastoma (GB) is an aggressive malignant central nervous system tumor that is currently incurable. One of the main pitfalls of GB treatment is resistance to the chemotherapeutic standard of care, temozolomide (TMZ). The role of aldehyde dehydrogenases (ALDHs) in the glioma stem cell (GSC) subpopulation has been related to chemoresistance. ALDHs take part in processes such as cell proliferation, differentiation, invasiveness or metastasis and have been studied as pharmacological targets in cancer treatment. In the present work, three novel α,β-acetylenic amino thiolester compounds, with demonstrated efficacy as ALDH inhibitors, were tested in vitro on a panel of six human GB cell lines and one murine GB cell line. Firstly, the expression of the ALDH1A isoforms was assessed, and then inhibitors were tested for their cytotoxicity and their ability to inhibit cellular ALDH activity. Drug combination assays with TMZ were performed, as well as an assessment of the cell death mechanism and generation of ROS. A knockout of several ALDH genes was carried out in one of the human GB cell lines, allowing us to discuss their role in cell proliferation, migration capacity and resistance to treatment. Our results strongly suggest that ALDH inhibitors could be an interesting approach in the treatment of GB, with EC50 values in the order of micromolar, decreasing ALDH activity in GB cell lines to 40-50%.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Chromatic Nanoswitcher for Thermal Monitoring of Cell Metabolism

  • Zhang, Fengchan|||0000-0003-0751-1009
  • París Ogáyar, Marina|||0000-0002-4816-7729
  • Artiga, Álvaro|||0000-0001-9475-6367
  • Hernando, Jordi|||0000-0002-1126-4138
  • Villar-Alvarez, Eva|||0000-0003-4023-1375
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Salegi Ansa, Beñat|||0000-0001-5054-758X
  • Cogliati, Sara|||0000-0002-0374-3489
  • Formentini, Laura|||0000-0001-5641-821X
  • Haro-González, Patricia|||0000-0002-1568-3794
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
  • Otaegui, Jaume Ramon|||0000-0002-9596-8625
  • Roscini, Claudio|||0000-0002-0157-8934
  • Jaque, Daniel|||0000-0002-3225-0667
Accurate sensing of intracellular temperature is crucial for understanding and monitoring cell metabolism, serving as an initial step toward diagnosing conditions such as mitochondria-related diseases. However, thermal monitoring of cell metabolism is challenging due to the minimal temperature variations caused by intracellular metabolic activity (typically ≈1 °C) and by the risk of crosstalk in intracellular sensors. A novel type of intracellular thermal sensor is presented, based on silica nanocapsules filled with a thermo-responsive fluorescent medium. This medium undergoes a reversible phase transition from solid to liquid at temperatures ≈37 °C, inducing a chromatic switch that facilitates remote thermal sensing. The chromatic switchers exhibit a thermal sensitivity of ≈13% °C⁻¹ at 37 °C, one of the highest reported for intracellular thermal sensing. Notably, the thermal response is unaffected by external factors such as pH, ionic strength, and viscosity. Moreover, it is confirmed that the response of the sensors is not affected by the cellular activity, underscoring their reliability for cytoplasmic temperature measurements. The potential of these sensors is demonstrated by measuring intracellular heating during the metabolic switch from mitochondrial to glycolytic activity, showcasing their potential for real-time, precise thermal monitoring (<1 °C) of cell metabolism.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Combining experimental and computational tools to unravel copper-based metallodrug interactions with proteins

  • Peña Aparicio, Joaquim|||0000-0001-6477-8127
  • Zapirain Gysling, Iker|||0000-0001-5117-7082
  • Simaan, A. Jalila|||0000-0003-2537-0422
  • Capdevila, Mercè|||0000-0002-2246-0994
  • Iranzo, Olga|||0000-0001-8542-2429
  • Palacios, Òscar|||0000-0002-2987-7303
  • Maréchal, Jean-Didier|||0000-0002-8344-9043
  • Bayón, Pau|||0000-0002-3064-8866
Metallodrugs are widely used in the treatment of several diseases, including cancer. Many bloodstream proteins exhibit high affinities for metals and metal-based compounds, and these interactions have been shown to impact metallodrug pharmacokinetics and pharmacodynamics, ultimately influencing their therapeutic performance. Several spectroscopic, spectrometric, and computational techniques have been used to further understand drug-protein binding modes at the molecular level over the last few years. However, there is still plenty of room to ascertain the full potential of integrated experimental-computational methodologies in the field of metallodrugs. These studies have mostly been limited to a few metal-containing systems, such as platinates and vanadium drugs. In this work, we aim to expand and validate the use of combined experimental-theoretical approaches in studying copper (Cu)-based drug interactions with proteins. To do so, a tetracoordinated Cu(II) complex has been employed as a practical case study, and its interactions with several relevant proteins using different experimental and computational techniques have been evaluated, including electron paramagnetic resonance spectroscopy, mass spectrometry, density functional theory, and protein-ligand docking calculations. Experimental data highlight interactions of the Cu(II) complex with albumin, myoglobin, and cytochrome C. Further insights into the preferential modes of binding were evaluated by density functional theory and docking calculations, which revealed three main outer surface binding sites for both albumin and myoglobin, as well as three preferential inner pockets in the case of albumin. The most relevant binding modes found for both proteins include noncoordinative interactions with the Cu(II) dimeric structure intact upon binding, as well as metal-ligand exchange and direct metal-amino acid coordination, mainly to glutamate/aspartate residues after cleavage of the dimer. Altogether, an example of the applicability of a mixed experimental-theoretical framework in the study of Cu-based drug interactions with relevant proteins is shown.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Bioinspired neuromelanin-like Pt(iv) polymeric nanoparticles for cancer treatment

  • Gómez Herrera, Roger
  • Alfonso Triguero, Paula|||0000-0002-6554-5656
  • Mao, Xiaoman
  • Mancebo Aracil, Juan|||0000-0003-2627-9161
  • Montpeyó, David|||0000-0002-0327-2015
  • Novio, Fernando|||0000-0002-1517-3612
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
To expand the chemotherapeutic potential of platinum complexes, different approaches have been followed, two of the most relevant being their administration as the prodrug Pt(iv) and encapsulation in nanocarriers. Herein, we demonstrate how neuromelanin may become a good bioinspiration for the synthesis of nanoparticles (NPs), combining both approaches. For this, complex PtBC reacts with sodium periodate, inducing a melanization process and the formation of nanoparticles. In vitro results on non-malignant human fibroblast cells (1Br3G), human cervical cancer, murine glioma (GL261), and human ovarian cancer confirmed its therapeutic efficacy. The role of the Pt(iv) ion on the cytotoxicity effects was confirmed by comparison with the results obtained for a family of nanoparticles obtained with nordihydroguaiaretic acid under the same experimental conditions. Finally, intranasal administration of the NPs in orthotopic glioblastoma multiforme murine models in female C57BL/6 mice showed excellent in vivo biodistribution and tolerability. Overall, this innovative approach represents a step toward more specific and less toxic therapies in the field of cancer chemotherapy.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Development of New Targeted Nanotherapy Combined with Magneto-Fluorescent Nanoparticles against Colorectal Cancer

  • Marcelo, Goncalo A.
  • Montpeyó, David
  • Galhano, Joana
  • Capelo-Martínez, José Luis
  • Lorenzo, Julia
  • Lodeiro, Carlos
  • Oliveira, Elisabete
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] The need for non-invasive therapies capable of conserving drug efficiency and stability while having specific targetability against colorectal cancer (CRC), has made nanoparticles preferable vehicles and principal building blocks for the development of complex and multi-action anti-tumoral approaches. For that purpose, we herein report the production of a combinatory anti-tumoral nanotherapy using the production of a new targeting towards CRC lines. To do so, Magneto-fluorescent NANO3 nanoparticles were used as nanocarriers for a combination of the drugs doxorubicin (DOX) and ofloxacin (OFLO). NANO3 nanoparticles' surface was modified with two different targeting agents, a newly synthesized (anti-CA IX acetazolamide derivative (AZM-SH)) and a commercially available (anti-epidermal growth factor receptor (EGFR), Cetuximab). The cytotoxicity revealed that only DOX-containing nanosystems showed significant and even competitive cytotoxicity when compared to that of free DOX. Interestingly, surface modification with AZM-SH promoted an increased cellular uptake in the HCT116 cell line, surpassing even those functionalized with Cetuximab. The results show that the new target has high potential to be used as a nanotherapy agent for CRC cells, surpassing commercial targets. As a proof-of-concept, an oral administration form of NANO3 systems was successfully combined with Eudragit (R) enteric coating and studied under extreme conditions., This work received financial support from PT national funds (FCT/MCTES, Fundacao para a Ciencia e Tecnologia and Ministerio da Ciencia, Tecnologia e Ensino Superior) through the projects UIDB/50006/2020 and UIDP/50006/2020. G.M. acknowledges the financial support by the Associate Laboratory Research Unit for Green Chemistry-Clean Processes and Technologies-LAQV, which is financed by national funds from FCT/MEC (UID/QUI/50006/2013) and co-financed by the ERDF under the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007265), as well as the Scientific Society PROTEOMASS (Portugal) for funding support (General Funding Grant). G.M. and J.G. thank FCT/MEC (Portugal) for their doctoral grant PD/BD/142865/2018 and 2022.09495.BD, respectively. E.O. thanks FCT (Fundacao para a Ciencia e Tecnologia) for funding through the Scientific Employment Stimulus-Individual Call (Ref. CEECIND/00648/2017). J.L. acknowledges the funding received from the Ministerio de Ciencia, Innovacion y Universidades, Spain, grant PID2021-127983OB-C22 funded by MCIN/AEI/10.13039/501100011033. RMM acknowledges the funding received from project PID2021-126304OB-C41 funded by MCIN/AEI /10.13039/501100011033/ and by European Regional Development Fund-A way of doing Europe and Generalitat Valenciana (CIPROM/2021/007).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Platinum-based nanoformulations for glioblastoma treatment: the resurgence of platinum drugs?

  • Alfonso Triguero, Paula
  • Lorenzo, Julia
  • Candiota, Ana Paula
  • Arús, Carles
  • Ruiz Molina, Daniel
  • Novio, Fernando
This article belongs to the Special Issue Current Review in Nanofabrication and Nanomanufacturing., Current therapies for treating Glioblastoma (GB), and brain tumours in general, are inefficient and represent numerous challenges. In addition to surgical resection, chemotherapy and radiotherapy are presently used as standards of care. However, treated patients still face a dismal prognosis with a median survival below 15–18 months. Temozolomide (TMZ) is the main chemotherapeutic agent administered; however, intrinsic or acquired resistance to TMZ contributes to the limited efficacy of this drug. To circumvent the current drawbacks in GB treatment, a large number of classical and non-classical platinum complexes have been prepared and tested for anticancer activity, especially platinum (IV)-based prodrugs. Platinum complexes, used as alkylating agents in the anticancer chemotherapy of some malignancies, are though often associated with severe systemic toxicity (i.e., neurotoxicity), especially after long-term treatments. The objective of the current developments is to produce novel nanoformulations with improved lipophilicity and passive diffusion, promoting intracellular accumulation, while reducing toxicity and optimizing the concomitant treatment of chemo-/radiotherapy. Moreover, the blood–brain barrier (BBB) prevents the access of the drugs to the brain and accumulation in tumour cells, so it represents a key challenge for GB management. The development of novel nanomedicines with the ability to (i) encapsulate Pt-based drugs and pro-drugs, (ii) cross the BBB, and (iii) specifically target cancer cells represents a promising approach to increase the therapeutic effect of the anticancer drugs and reduce undesired side effects. In this review, a critical discussion is presented concerning different families of nanoparticles able to encapsulate platinum anticancer drugs and their application for GB treatment, emphasizing their potential for increasing the effectiveness of platinum-based drugs., This research was supported by grant PID2021-127983OB-C21, PID2021-127983OB-C22, and PID2020-113058GB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF A way of making Europe and by PI21/00181 from the Instituto Carlos III. The ICN2 is funded by the CERCA programme/Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centres of Excellence programme, Grant CEX2021-001214-S, funded by MCIN/AEI/10.13039.501100011033. This work was also supported by the Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001214-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Targeting Retinaldehyde Dehydrogenases to Enhance Temozolomide Therapy in Glioblastoma

  • Jiménez, Rafael
  • Constantinescu, Andrada
  • Yazir, Muhube
  • Alfonso Triguero, Paula
  • Pequerul, Raquel
  • Parés, Xavier
  • Pérez-Alea, Mileidys
  • Candiota, Ana Paula
  • Farrés, Jaume
  • Lorenzo, Julia
Glioblastoma (GB) is an aggressive malignant central nervous system tumor that is currently incurable. One of the main pitfalls of GB treatment is resistance to the chemotherapeutic standard of care, temozolomide (TMZ). The role of aldehyde dehydrogenases (ALDHs) in the glioma stem cell (GSC) subpopulation has been related to chemoresistance. ALDHs take part in processes such as cell proliferation, differentiation, invasiveness or metastasis and have been studied as pharmacological targets in cancer treatment. In the present work, three novel α,β-acetylenic amino thiolester compounds, with demonstrated efficacy as ALDH inhibitors, were tested in vitro on a panel of six human GB cell lines and one murine GB cell line. Firstly, the expression of the ALDH1A isoforms was assessed, and then inhibitors were tested for their cytotoxicity and their ability to inhibit cellular ALDH activity. Drug combination assays with TMZ were performed, as well as an assessment of the cell death mechanism and generation of ROS. A knockout of several ALDH genes was carried out in one of the human GB cell lines, allowing us to discuss their role in cell proliferation, migration capacity and resistance to treatment. Our results strongly suggest that ALDH inhibitors could be an interesting approach in the treatment of GB, with EC50 values in the order of micromolar, decreasing ALDH activity in GB cell lines to 40–50%., This research was funded by the Spanish Ministerio de Ciencia e Innovación (Agencia Estatal de Investigación, grant numbers PID2020-119424RB-I00, PID2020-113058GB-I00, PID2021-127983OB-C22/AEI/10.13039/501100011033). This research was also supported by Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, grup consolidat N-TETRASCAN 2021SGR00135). R.P. obtained financial support from the company Advanced BioDesign through a research contract agreement with Universitat Autònoma de Barcelona. This work was also supported by Centro de Investigación Biomédica en Red-Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN [https://www.ciber-bbn.es/en, accessed on 26 August 2024], CB06/01/0010), an initiative of the Instituto de Salud Carlos III (Spain). R.J. was a recipient of a PIF predoctoral fellowship from Universitat Autònoma de Barcelona., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bioinspired neuromelanin-like Pt(iv) polymeric nanoparticles for cancer treatment

  • Gómez-Herrera, Roger
  • Alfonso Triguero, Paula
  • Mao, Xiaoman
  • Mancebo-Aracil, Juan
  • Montpeyó, David
  • Novio, Fernando
  • Lorenzo, Julia
  • Ruiz Molina, Daniel
To expand the chemotherapeutic potential of platinum complexes, different approaches have been followed, two of the most relevant being their administration as the prodrug Pt(iv) and encapsulation in nanocarriers. Herein, we demonstrate how neuromelanin may become a good bioinspiration for the synthesis of nanoparticles (NPs), combining both approaches. For this, complex PtBC reacts with sodium periodate, inducing a melanization process and the formation of nanoparticles. In vitro results on non-malignant human fibroblast cells (1Br3G), human cervical cancer, murine glioma (GL261), and human ovarian cancer confirmed its therapeutic efficacy. The role of the Pt(iv) ion on the cytotoxicity effects was confirmed by comparison with the results obtained for a family of nanoparticles obtained with nordihydroguaiaretic acid under the same experimental conditions. Finally, intranasal administration of the NPs in orthotopic glioblastoma multiforme murine models in female C57BL/6 mice showed excellent in vivo biodistribution and tolerability. Overall, this innovative approach represents a step toward more specific and less toxic therapies in the field of cancer chemotherapy., This work was supported by grants PID2021-127983OB-C21 and PID2021-127983OB-C22 funded by MCIN/AEI/10.13039/501100011033/and ERDF. A way of making Europe. F. N. acknowledges support by grant CNS2022-136106 funded by MICIU/AEI/10.13039/501100011033 and by European Union NextGeneration EU/PRTR. The ICN2 is funded by the CERCA program/Generalitat de Catalunya and supported by the Severo Ochoa Centres of Excellence program, grant CEX2021-001214-S, funded by MCIN/AEI/10.13039.501100011033., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001214-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multimodal HOCl-responsive MEH-PPV nanoparticles for anti-inflammatory imaging and therapy

  • Villar-Álvarez, Eva
  • Parron-Onate, Sara
  • Wienskowska, Olga
  • Carrascull-Marín, Aleix
  • Bellacanzone, Christian
  • Lorenzo, Julia
  • Ruiz Molina, Daniel
  • Roscini, Claudio
Inflammatory disorders often correlate with an unusually high intracellular production of hypochlorous acid (HOCl). Therefore, its rapid, sensitive, and specific detection is crucial for an early diagnosis and treatment evaluation. While nanoparticles for detection have already been reported, multimodal nanoparticles that simultaneously detect and eliminate reactive oxygen species (including the excess of HOCl) are scarce despite their interest. Herein, we developed highly selective fluorescent nanoparticles using the copolymer poly(2-methoxy-5-(2-ethylhexyloxy)-1, 4-phenylenevinylene) (MEH-PPV), with (MEH@CS) and without a chitosan coating (MEH). The conjugated polymer is oxidized in the presence of HOCl, exhibiting a rapid (in less than 30 s) and sensitive fluorescence turn-off response with a log-log linear HOCl relationship within dynamic ranges of ≈ 0.784–83 μM and ≈ 0.384–55 μM for MEH and MEH@CS NPs, respectively, allowing to monitor basal HOCl levels within the standard physiological concentration range (5 – 25 μM) and its differentiation from overproduction. Moreover, the nanoparticles can encapsulate and release quercetin (a powerful natural scavenger for HOCl), leading not only to monitoring but also to a reduction in pro-inflammatory cytokines of inflammation-stimulated macrophage cells., We would like to acknowledge the “Cell cultures, Antibody production and Cytometry Services” of the Institut de Biotecnologia i de Biomedicina (IBB) placed associated to the Universitat Autònoma de Barcelona (UAB) for their collaboration in cell culture and cytometric assays. E.V.A. acknowledges her Juan de la Cierva-formación fellowship FJC2018–036356-I. This work was supported by grants PID2021–127983OB-C21 and PID2021–127983OB-C22 funded by MCIU/AEI/10.13039/501100011033/ and ERDF A way of making Europe, and 2021SGR00135. The ICN2 is funded by the CERCA program/Generalitat de Catalunya and supported by the Severo Ochoa Centres of Excellence programme, Grant CEX2021-001214-S, funded by MCIU/AEI/10.13039.501100011033, With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001214-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mussel-inspired multifunctional polyethylene glycol nanoparticle interfaces

  • Casagualda, Carolina
  • López-Moral, Alba
  • Alfonso Triguero, Paula
  • Lorenzo, Julia
  • Alibés, Ramón
  • Busqué, Félix
  • Ruiz Molina, Daniel
This article belongs to the Special Issue Advances in Biomimetics: The Power of Diversity., Nanoparticles (NPs) are receiving increasing interest in biomedical applications. However, due to their large surface area, in physiological environments, they tend to interact with plasma proteins, inducing their agglomeration and ultimately resulting in a substantial efficiency decrease in diagnostic and therapeutic applications. To overcome such problems, NPs are typically coated with a layer of hydrophilic and biocompatible polymers, such as PEG chains. However, few examples exist in which this property could be systematically fine-tuned and combined with added properties, such as emission. Herein, we report a novel mussel-inspired catechol-based strategy to obtain biocompatible and multifunctional coatings, using a previously developed polymerization methodology based on the formation of disulfide bridges under mild oxidative conditions. Two families of NPs were selected as the proof of concept: mesoporous silica NPs (MSNPs), due to their stability and known applications, and magnetite NPs (Fe3O4 NPs), due to their small size (<10 nm) and magnetic properties. The PEG coating confers biocompatibility on the NPs and can be further functionalized with bioactive molecules, such as glucose units, through the end carboxylic acid moieties. Once we demonstrated the feasibility of our approach to obtaining PEG-based coatings on different families of NPs, we also obtained multifunctional coatings by incorporating fluorescein functionalities. The resulting coatings not only confer biocompatibility and excellent cell internalization, but also allow for the imaging and tracking of NPs within cells., Funding support from the following grants: PID2019-106403RB-I00, PID2021-127983OB-C21, PID2021-127983OB-C22, and PID2022-139826OB-I00, funded by MCIN/AEI/10.13039/501100011033, co-financed with the European Fund for Regional Development (FEDER), and by ERDF’s “A way of making Europe”. The ICN2 is funded by the CERCA program/Generalitat de Catalunya. The ICN2 is supported by the Severo Ochoa Centers of Excellence program, and grant SEV-2017-0706 is funded by MCIN/AEI/10.13039/501100011033., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Chromatic Nanoswitcher for Thermal Monitoring of Cell Metabolism

  • Zhang, Fengchan
  • París Ogáyar, Marina
  • Artiga, Álvaro
  • Hernando, Jordi
  • Villar-Álvarez, Eva
  • Lorenzo, Julia
  • Salegi, Beñat
  • Cogliati, Sara
  • Formentini, Laura
  • Haro-González, Patricia
  • Ruiz Molina, Daniel
  • Otaegui, Jaume R.
  • Roscini, Claudio
  • Jaque, Daniel
Accurate sensing of intracellular temperature is crucial for understanding and monitoring cell metabolism, serving as an initial step toward diagnosing conditions such as mitochondria-related diseases. However, thermal monitoring of cell metabolism is challenging due to the minimal temperature variations caused by intracellular metabolic activity (typically ≈1 °C) and by the risk of crosstalk in intracellular sensors. A novel type of intracellular thermal sensor is presented, based on silica nanocapsules filled with a thermo-responsive fluorescent medium. This medium undergoes a reversible phase transition from solid to liquid at temperatures ≈37 °C, inducing a chromatic switch that facilitates remote thermal sensing. The chromatic switchers exhibit a thermal sensitivity of ≈13% °C⁻¹ at 37 °C, one of the highest reported for intracellular thermal sensing. Notably, the thermal response is unaffected by external factors such as pH, ionic strength, and viscosity. Moreover, it is confirmed that the response of the sensors is not affected by the cellular activity, underscoring their reliability for cytoplasmic temperature measurements. The potential of these sensors is demonstrated by measuring intracellular heating during the metabolic switch from mitochondrial to glycolytic activity, showcasing their potential for real-time, precise thermal monitoring (<1 °C) of cell metabolism., This work was supported by grants PID2021-127983OB-C21, PID2021-127983OB-C22, PID2022-141293OB-I00, TED2021-129937B–I00, CNS2022-135495, PID2023-151078OB-I00, and ID2023-146775OB-I00 (INCLINA)funded by Spanish Ministeryof Science and Universities MICIU/AEI/10.13039/501100011033 and by ERDF – “A way of making Europe”. This work has been supported by Comunidad de Madrid (S2022/BMD-7403 RENIM-CM). The ICN2 is supported by the Severo Ochoa Centres of Excellence program, Grant CEX2021-001214-S, funded by MICIU/AEI/10.13039.501100011033. UAB thanks the support from Generalitat de Catalunya (2021 SGR 00064 project). Authors acknowledge the use of instrumentation as well as the technical advice provided by the Joint Electron Microscopy Center at ALBA (JEMCA) and funding from Grant IU16-014206 (METCAM-FIB) to ICN2 funded by the European Union through the European Regional Development Fund (ERDF), with the support of the Ministry of Research and Universities, Generalitat de Catalunya. L.F. was supported by grant PID2022-136738OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by a grant of Fundación Ramón Areces. S.C. was supported by grant PID2020-114054RA-I00 and CNS2023-143646 funded by MICIU/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR. F.Z. acknowledges the scholarship from the China Scholarship Council (No. 202108440235). J.R.O. thanks the Generalitat de Catalunya (AGAUR) for his predoctoral FI fellowship. M.P.O. acknowledges the financial support from MICINN for an FPU (FPU20/03166). Á.A. is grateful for his Juan de la Cierva Fellowship Grant FJC2021-047006-I funded by MCIN/AEI/10.13039/501100011033 and by the “European Union NextGeneration EU/PRTR”. J.H. is a Serra Húnter Fellow. B.S.A. is supported by an FPU predoctoral grant (FPU2022/00218)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001214-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metal-Organic Framework-Based Antimicrobial Touch Surfaces to Prevent Cross-Contamination

  • Fonseca, Javier
  • Cano-Sarabia, Mary
  • Cortés, Pilar
  • Saldo, Jordi
  • Montpeyó, David
  • Lorenzo, Julia
  • Llagostera, Montserrat
  • Imaz, Inhar
  • Maspoch, Daniel
Special Issue: 30 Years of Reticular Materials, Infection diseases are a major threat to global public health, with nosocomial infections being of particular concern. In this context, antimicrobial coatings emerge as a promising prophylactic strategy to reduce the transmission of pathogens and control infections. Here, antimicrobial door handle covers to prevent cross-contamination are prepared by incorporating iodine-loaded UiO-66 microparticles into a potentially biodegradable polyurethane polymer (Baycusan eco E 1000). These covers incorporate MOF particles that serve as both storage reservoirs and delivery systems for the biocidal iodine. Under realistic touching conditions, the door handle covers completely inhibit the transmission of Gram-positive bacterial species (Staphylococcus aureus, and Enterococcus faecalis), Gram-negative bacterial species (Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii), and fungi (Candida albicans). The covers remain effective even after undergoing multiple contamination cycles, after being cleaned, and when tinted to improve discretion and usability. Furthermore, as the release of iodine from the door handle covers follow hindered Fickian diffusion, their antimicrobial lifetime is calculated to be as long as approximately two years. Together, these results demonstrate the potential of these antimicrobial door handle covers to prevent cross-contamination, and underline the efficacy of integrating MOFs into innovative technologies., This work was funded by the European Research Council Executive Agency under the powers delegated by the European Commission, Project 101062041 – SAFE-ON, the Catalan AGAUR (project 2017 SGR 238), the MCIN/AEI/10.13039/501100011033 (project PID2021-127983OB-C22), and the CERCA Program/Generalitat de Catalunya. ICN2 was supported by the Severo Ochoa program from the Spanish MINECO (grant CEX2021-001214-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excelence" accreditation (CEX2021-001214-S), Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Enhanced Production of ECM Proteins for Pharmaceutical Applications Using Mammalian Cells and Sodium Heparin Supplementation

  • Garcia-Pardo, Javier|||0000-0001-9179-6371
  • Montané, Sergi|||0000-0002-8855-5662
  • Avilés, Francesc Xavier|||0000-0002-1399-6789
  • Tanco, Sebastián Martín|||0000-0003-2130-4401
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
The yields of soluble ECM proteins recombinantly produced with mammalian cells can be significantly enhanced by exploiting the stabilizing properties of heparin. Here, we propose a simple and straightforward scalable protocol for the mammalian cell production of ECM proteins with affinity for heparin, using heparin as a supplement. As proof of concept, we have demonstrated the high-level expression of four biomedically relevant human enzymes such as carboxypeptidase Z (CPZ), carboxypeptidase A6 (CPA6), beta-galactoside alpha-2,6-sialyltransferase 2 (ST6GAL1) and thrombin-activable fibrinolysis inhibitor (TAFI). We found a strong linear correlation between the isoelectric point (pI) of a protein and the improvement in protein expression levels upon heparin addition, providing a reference for selecting novel protein targets that would benefit from heparin supplementation. Finally, we demonstrated the compatibility of this approach with a three-step purification strategy that includes an initial heparin affinity purification step. Using CPZ as a representative example, we performed a preparative purification of this enzyme. The purified protein is enzymatically active and can be used for pharmaceutical applications as well as for high-throughput functional and structural studies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cell-penetrating peptide-conjugated copper complexes for redox-mediated anticancer therapy

  • Peña Aparicio, Joaquim|||0000-0001-6477-8127
  • Rodriguez-Calado, Sergi|||0000-0002-8849-1101
  • Simaan, A. Jalila|||0000-0003-2537-0422
  • Capdevila, Mercè|||0000-0002-2246-0994
  • Bayón, Joan Carles|||0000-0002-2498-1945
  • Palacios, Òscar|||0000-0002-2987-7303
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Iranzo, Olga|||0000-0001-8542-2429
Metal-based chemotherapeutics like cisplatin are widely employed in cancer treatment. In the last years, the design of redox-active (transition) metal complexes, such as of copper (Cu), has attracted high interest as alternatives to overcome platinum-induced side-effects. However, several challenges are still faced, including optimal aqueous solubility and efficient intracellular delivery, and strategies like the use of cell-penetrating peptides have been encouraging. In this context, we previously designed a Cu(II) scaffold that exhibited significant reactive oxygen species (ROS)-mediated cytotoxicity. Herein, we build upon the promising Cu(II) redox-active metallic core and aim to potentiate its anticancer activity by rationally tailoring it with solubility- and uptake-enhancing functionalizations that do not alter the ROS-generating Cu(II) center. To this end, sulfonate, arginine and arginine-rich cell-penetrating peptide (CPP) derivatives have been prepared and characterized, and all the resulting complexes preserved the parent Cu(II) coordination core, thereby maintaining its reported redox capabilities. Comparative in vitro assays in several cancer cell lines reveal that while specific solubility-targeting derivatizations (i.e., sulfonate or arginine) did not translate into an improved cytotoxicity, increased intracellular copper delivery via CPP-conjugation promoted an enhanced anticancer activity, already detectable at short treatment times. Additionally, immunofluorescence assays show that the Cu(II) peptide-conjugate distributed throughout the cytosol without lysosomal colocalization, suggesting potential avoidance of endosomal entrapment. Overall, the systematic exploration of the tailored modifications enables us to provide further understanding on structure-activity relationships of redox-active metal-based (Cu(II)) cytotoxic complexes, which contributes to rationalize and improve the design of more efficient redox-mediated metal-based anticancer therapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Proximity Mapping of CCP6 Reveals Its Association with Centrosome Organization and Cilium Assembly

  • Rodriguez-Calado, Sergi|||0000-0002-8849-1101
  • Van Damme, Petra|||0000-0001-9090-027X
  • Avilés, Francesc Xavier|||0000-0002-1399-6789
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Tanco, Sebastián Martín|||0000-0003-2130-4401
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
The cytosolic carboxypeptidase 6 (CCP6) catalyzes the deglutamylation of polyglutamate side chains, a post-translational modification that affects proteins such as tubulins or nucleosome assembly proteins. CCP6 is involved in several cell processes, such as spermatogenesis, antiviral activity, embryonic development, and pathologies like renal adenocarcinoma. In the present work, the cellular role of CCP6 has been assessed by BioID, a proximity labeling approach for mapping physiologically relevant protein-protein interactions (PPIs) and bait proximal proteins by mass spectrometry. We used HEK 293 cells stably expressing CCP6-BirA* to identify 37 putative interactors of this enzyme. This list of CCP6 proximal proteins displayed enrichment of proteins associated with the centrosome and centriolar satellites, indicating that CCP6 could be present in the pericentriolar material. In addition, we identified cilium assembly-related proteins as putative interactors of CCP6. In addition, the CCP6 proximal partner list included five proteins associated with the Joubert syndrome, a ciliopathy linked to defects in polyglutamylation. Using the proximity ligation assay (PLA), we show that PCM1, PIBF1, and NudC are true CCP6 physical interactors. Therefore, the BioID methodology confirms the location and possible functional role of CCP6 in centrosomes and centrioles, as well as in the formation and maintenance of primary cilia.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development of New Targeted Nanotherapy Combined with Magneto-Fluorescent Nanoparticles against Colorectal Cancer

  • Marcelo, Gonçalo A.|||0000-0003-1248-085X
  • Montpeyó, David|||0000-0002-0327-2015
  • Galhano, Joana|||0000-0002-7149-1682
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Capelo-Martínez, José Luis|||0000-0001-6276-8507
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Lodeiro, Carlos|||0000-0001-5582-5446
  • Oliveira, Elisabete|||0000-0002-8339-4820
The need for non-invasive therapies capable of conserving drug efficiency and stability while having specific targetability against colorectal cancer (CRC), has made nanoparticles preferable vehicles and principal building blocks for the development of complex and multi-action anti-tumoral approaches. For that purpose, we herein report the production of a combinatory anti-tumoral nanotherapy using the production of a new targeting towards CRC lines. To do so, Magneto-fluorescent NANO3 nanoparticles were used as nanocarriers for a combination of the drugs doxorubicin (DOX) and ofloxacin (OFLO). NANO3 nanoparticles' surface was modified with two different targeting agents, a newly synthesized (anti-CA IX acetazolamide derivative (AZM-SH)) and a commercially available (anti-epidermal growth factor receptor (EGFR), Cetuximab). The cytotoxicity revealed that only DOX-containing nanosystems showed significant and even competitive cytotoxicity when compared to that of free DOX. Interestingly, surface modification with AZM-SH promoted an increased cellular uptake in the HCT116 cell line, surpassing even those functionalized with Cetuximab. The results show that the new target has high potential to be used as a nanotherapy agent for CRC cells, surpassing commercial targets. As a proof-of-concept, an oral administration form of NANO3 systems was successfully combined with Eudragit ® enteric coating and studied under extreme conditions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Platinum-Based Nanoformulations for Glioblastoma Treatment, The Resurgence of Platinum Drugs?

  • Alfonso Triguero, Paula|||0000-0002-6554-5656
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
  • Novio, Fernando|||0000-0002-1517-3612
Current therapies for treating Glioblastoma (GB), and brain tumours in general, are inefficient and represent numerous challenges. In addition to surgical resection, chemotherapy and radiotherapy are presently used as standards of care. However, treated patients still face a dismal prognosis with a median survival below 15-18 months. Temozolomide (TMZ) is the main chemotherapeutic agent administered; however, intrinsic or acquired resistance to TMZ contributes to the limited efficacy of this drug. To circumvent the current drawbacks in GB treatment, a large number of classical and non-classical platinum complexes have been prepared and tested for anticancer activity, especially platinum (IV)-based prodrugs. Platinum complexes, used as alkylating agents in the anticancer chemotherapy of some malignancies, are though often associated with severe systemic toxicity (i.e., neurotoxicity), especially after long-term treatments. The objective of the current developments is to produce novel nanoformulations with improved lipophilicity and passive diffusion, promoting intracellular accumulation, while reducing toxicity and optimizing the concomitant treatment of chemo-/radiotherapy. Moreover, the blood-brain barrier (BBB) prevents the access of the drugs to the brain and accumulation in tumour cells, so it represents a key challenge for GB management. The development of novel nanomedicines with the ability to (i) encapsulate Pt-based drugs and pro-drugs, (ii) cross the BBB, and (iii) specifically target cancer cells represents a promising approach to increase the therapeutic effect of the anticancer drugs and reduce undesired side effects. In this review, a critical discussion is presented concerning different families of nanoparticles able to encapsulate platinum anticancer drugs and their application for GB treatment, emphasizing their potential for increasing the effectiveness of platinum-based drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Roadmap on nanomedicine for the central nervous system

  • Ciofani, Gianni|||0000-0003-1192-3647
  • Campisi, Marco
  • Mattu, Clara
  • Kamm, Roger D.|||0000-0002-7232-304X
  • Chiono, Valeria|||0000-0003-2067-7732
  • Raynold, Aji Alex Moothedathu
  • Freitas, João S.
  • Redolfi Riva, Eugenio
  • Micera, Silvestro|||0000-0003-4396-8217
  • Pucci, Carlotta
  • Novio, Fernando|||0000-0002-1517-3612
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Ruiz-Molina, Daniel|||0000-0002-6844-8421
  • Sierri, Giulia
  • Re, Francesca
  • Wunderlich, Hannah
  • Kumari, Prachi
  • Kozielski, Kristen L.|||0000-0003-3504-2318
  • Chami, Mounia|||0000-0003-1498-7187
  • Marino, Attilio
  • Ferreira, Lino|||0000-0001-8985-9302
In recent years, a great deal of effort has been undertaken with regards to treatment of pathologies at the level of the central nervous system (CNS). Here, the presence of the blood-brain barrier acts as an obstacle to the delivery of potentially effective drugs and makes accessibility to, and treatment of, the CNS one of the most significant challenges in medicine. In this Roadmap article, we present the status of the timeliest developments in the field, and identify the outstanding challenges and opportunities that exist. The format of the Roadmap, whereby experts in each discipline share their viewpoint and present their vision, reflects the dynamic and multidisciplinary nature of this research area, and is intended to generate dialogue and collaboration across traditional subject areas. It is stressed here that this article is not intended to act as a comprehensive review article, but rather an up-to-date and forward-looking summary of research methodologies pertaining to the treatment of pathologies at the level of the CNS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Metal-Organic Framework-Based Antimicrobial Touch Surfaces to Prevent Cross-Contamination

  • Fonseca, Javier
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Cortés Garmendia, M. Pilar|||0000-0002-5924-0653
  • Saldo Periago, Jordi|||0000-0001-5166-6142
  • Montpeyó, David|||0000-0002-0327-2015
  • Lorenzo Rivera, Julia|||0000-0001-5659-6008
  • Llagostera Casas, Montserrat|||0000-0001-8177-8321
  • Imaz, Inhar|||0000-0002-0278-1141
  • Maspoch, Daniel|||0000-0003-1325-9161
Infection diseases are a major threat to global public health, with nosocomial infections being of particular concern. In this context, antimicrobial coatings emerge as a promising prophylactic strategy to reduce the transmission of pathogens and control infections. Here, antimicrobial door handle covers to prevent cross-contamination are prepared by incorporating iodine-loaded UiO-66 microparticles into a potentially biodegradable polyurethane polymer (Baycusan eco E 1000). These covers incorporate MOF particles that serve as both storage reservoirs and delivery systems for the biocidal iodine. Under realistic touching conditions, the door handle covers completely inhibit the transmission of Gram-positive bacterial species (Staphylococcus aureus, and Enterococcus faecalis), Gram-negative bacterial species (Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii), and fungi (Candida albicans). The covers remain effective even after undergoing multiple contamination cycles, after being cleaned, and when tinted to improve discretion and usability. Furthermore, as the release of iodine from the door handle covers follow hindered Fickian diffusion, their antimicrobial lifetime is calculated to be as long as approximately two years. Together, these results demonstrate the potential of these antimicrobial door handle covers to prevent cross-contamination, and underline the efficacy of integrating MOFs into innovative technologies.